- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Crohn Disease Ulcerative colitis
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 950KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 452KB)
Vedolizumab – March 2024
Vedolizumab: Injection 108 mg in 0.68 mL single use pre filled pen, Powder for injection 300 mg; Entyvio®
Last updated
30 May 2025